Literature DB >> 27941765

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML.

F Legrand1, A-C Le Floch1, A Granata1, S Fürst1, C Faucher1, C Lemarie2,3, S Harbi1, S Bramanti4, B Calmels2,3,5, J El-Cheikh1,6, C Chabannon2,3,5,7, P-J Weiller1,7, N Vey1,5,7,8, L Castagna6, D Blaise1,5,7,8, R Devillier1,5,7,8.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27941765     DOI： 10.1038/bmt.2016.326

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia.

Authors:  Alida Dominietto; Sarah Pozzi; Maurizio Miglino; Flavio Albarracin; Giovanna Piaggio; Francesca Bertolotti; Raffaella Grasso; Simona Zupo; Anna Maria Raiola; Marco Gobbi; Francesco Frassoni; Andrea Bacigalupo
Journal:  Blood       Date:  2007-06-01       Impact factor: 22.113

2.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.

Authors:  Marcos de Lima; David L Porter; Minoo Battiwalla; Michael R Bishop; Sergio A Giralt; Nancy M Hardy; Nicolaus Kröger; Alan S Wayne; Christoph Schmid
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-07       Impact factor: 5.742

3.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

Authors:  S Giralt; E Estey; M Albitar; K van Besien; G Rondón; P Anderlini; S O'Brien; I Khouri; J Gajewski; R Mehra; D Claxton; B Andersson; M Beran; D Przepiorka; C Koller; S Kornblau; M Kørbling; M Keating; H Kantarjian; R Champlin
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

4.  Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience.

Authors:  Jean El-Cheikh; Roberto Crocchiolo; Sabine Furst; Patrick Ladaique; Luca Castagna; Catherine Faucher; Boris Calmels; Claire Oudin; Claude Lemarie; Angela Granata; Raynier Devillier; Norbert Vey; Reda Bouabdallah; Christian Chabannon; Didier Blaise
Journal:  Exp Hematol       Date:  2012-09-25       Impact factor: 3.084

5.  High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.

Authors:  Maria Liga; Evangelia Triantafyllou; Maria Tiniakou; Polyxeni Lambropoulou; Marina Karakantza; Nicholas C Zoumbos; Alexandros Spyridonidis
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-04       Impact factor: 5.742

6.  Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.

Authors:  S R Solomon; C A Sizemore; X Zhang; S Brown; H K Holland; L E Morris; A Bashey
Journal:  Bone Marrow Transplant       Date:  2014-05       Impact factor: 5.483

7.  HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.

Authors:  Amer M Zeidan; Patrick M Forde; Heather Symons; Allen Chen; B Douglas Smith; Keith Pratz; Hetty Carraway; Douglas E Gladstone; Ephraim J Fuchs; Leo Luznik; Richard J Jones; Javier Bolaños-Meade
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-01       Impact factor: 5.742

8.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Authors:  Leo Luznik; Paul V O'Donnell; Heather J Symons; Allen R Chen; M Susan Leffell; Marianna Zahurak; Ted A Gooley; Steve Piantadosi; Michele Kaup; Richard F Ambinder; Carol Ann Huff; William Matsui; Javier Bolaños-Meade; Ivan Borrello; Jonathan D Powell; Elizabeth Harrington; Sandy Warnock; Mary Flowers; Robert A Brodsky; Brenda M Sandmaier; Rainer F Storb; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

9.  Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion.

Authors:  Matthias Eefting; Liesbeth C de Wreede; Constantijn J M Halkes; Peter A von dem Borne; Sabina Kersting; Erik W A Marijt; Hendrik Veelken; Hein Putter; Johannes Schetelig; J H Frederik Falkenburg
Journal:  Haematologica       Date:  2016-01-22       Impact factor: 9.941

10.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113
View more
  3 in total

Review 1.  Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering.

Authors:  Yishan Ye; Luxin Yang; Xiaolin Yuan; He Huang; Yi Luo
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

2.  Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor.

Authors:  Raynier Devillier; Boris Calmels; Sophie Guia; Mohammed Taha; Cyril Fauriat; Bechara Mfarrej; Geoffroy Venton; Eric Vivier; Daniel Olive; Christian Chabannon; Didier Blaise; Sophie Ugolini
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

Review 3.  T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.

Authors:  Valérie Janelle; Caroline Rulleau; Simon Del Testa; Cédric Carli; Jean-Sébastien Delisle
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.